Research advances in signaling pathways associated with potential anti-liver fibrosis drugs and targets
10.3969/j.issn.1001-5256.2023.12.027
- VernacularTitle:潜在抗肝纤维化药物与靶点相关信号通路研究进展
- Author:
Xin ZHOU
1
;
Zhi WANG
1
;
Xueru HE
1
;
Yuhao FU
1
;
Xuejiao XUN
1
;
Ying LI
2
;
Zhanjun DONG
2
Author Information
1. Graduate School of Hebei Medical University， Shijiazhuang 050017， China
2. Department of Pharmacy， Hebei General Hospital， Shijiazhuang 050057， China
- Publication Type:Review
- Keywords:
Hepatic Fibrosis;
Signal Transduction;
Pharmaceutical Preparations;
RNA， Untranslated
- From:
Journal of Clinical Hepatology
2023;39(12):2932-2941
- CountryChina
- Language:Chinese
-
Abstract:
Liver fibrosis is a key step in the progression of chronic liver diseases to liver cirrhosis and even liver cancer. In recent years， a large number of studies have shown the necessity of intervening in the process of liver fibrosis， and various anti-liver fibrosis drugs and active ingredients have been discovered. Non-coding RNAs also play an important role in the process of liver fibrosis， and searching for upstream non-coding RNAs that can regulate signaling pathways can provide new insights for anti-liver fibrosis treatment. This article introduces the process of liver fibrosis mediated by the TGF-β， Wnt/β-catenin， PI3K/Akt/mTOR， NF-κβ， Hippo， and MAPK signaling pathways， lists the latest anti-liver fibrosis drugs or active components in each signaling pathway， and summarizes the research advances in anti-liver fibrosis targets and drugs mediated by related non-coding RNAs， so as to provide new research ideas and treatment methods for anti-liver fibrosis treatment.
